Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Calithera Biosciences Inc CALA

Healthcare Biotechnology
Calithera Biosciences, Inc. is a shell company. The Company is winding up its operations. The Company is seeking to sell all of its clinical assets and programs. The Company has not generated any revenue.

Recent & Breaking News (GREY:CALA)

Calithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares

GlobeNewswire March 27, 2017

Calithera Biosciences, Inc. Prices Public Offering of 6,830,000 shares of Common Stock

GlobeNewswire March 22, 2017

Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock

GlobeNewswire March 20, 2017

Calithera Biosciences Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights

GlobeNewswire March 16, 2017

Calithera Biosciences to Report Fourth Quarter and Year-End 2016 Financial Results on Thursday, March 16, 2017

GlobeNewswire March 10, 2017

Calithera Biosciences to Present at Cowen and Company 37th Annual Health Care Conference

GlobeNewswire March 1, 2017

Calithera Biosciences to Present at the BIO CEO & Investor and Leerink Global Healthcare Conferences in February

GlobeNewswire February 9, 2017

15 Biggest Mid-Day Gainers For Monday

Benzinga.com  January 30, 2017

Mid-Day Market Update: Dow Falls Over 150 Points; Calithera Biosciences Shares Spike Higher

Benzinga.com  January 30, 2017

Mid-Morning Market Update: Markets Open Lower; Booz Allen Profit Misses Estimates

Benzinga.com  January 30, 2017

Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a First-in-class, Small Molecule Arginase Inhibitor

Business Wire January 30, 2017

Mid-Afternoon Market Update: Crude Oil Down 1.5%; Merus Shares Spike Higher

Benzinga.com  December 21, 2016

Mid-Morning Market Update: Markets Edge Lower; Finish Line Misses Q3 Expectations

Benzinga.com  December 21, 2016

Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma

Business Wire December 21, 2016

Calithera Biosciences to Host Conference Call and Webcast to Review Data Presented at the San Antonio Breast Cancer Symposium and EORTC-NCI-AACR Symposium

GlobeNewswire December 9, 2016

Calithera Biosciences Reports CB-839 Phase I Triple Negative Breast Cancer Combination Data at the 2016 San Antonio Breast Cancer Symposium

GlobeNewswire December 6, 2016

Calithera Biosciences Announces CB-839 Preclinical Data Selected for Presentation at the 58th American Society of Hematology Annual Meeting

GlobeNewswire December 2, 2016

Calithera Biosciences Reports CB-839 Phase I Renal Cell Carcinoma Combination Data at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

GlobeNewswire November 29, 2016

Calithera Biosciences Announces Four Abstracts Selected for Presentation at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting

GlobeNewswire November 11, 2016

Calithera Biosciences Reports Third Quarter 2016 Financial Results and Recent Highlights, and Raises Year-end Cash Guidance

GlobeNewswire November 9, 2016